Madeleine McNally

Cooley successfully secured the complete dismissal of a derivative action for FibroGen – a biopharmaceutical company that discovers and develops medicines for the treatment of anemia, cancer and fibrotic disease – as well as certain officers and directors. The case is In re FibroGen Inc. Derivative Litigation, C.A. No. 2022-0331-SG (Del. Ch.).

Cooley secured a key win on behalf of Talphera (formerly known as AcelRx Pharmaceuticals), a Silicon Valley-based specialty pharmaceutical company focused on the development and commercialization of innovative therapies, in a securities class action lawsuit brought by investors.

Cooley filed an amicus brief in the New York Court of Appeals on behalf of 47 corporate law professors in support of the continued application of the internal affairs doctrine.